SCHEMBL21218178

SCHEMBL21218178

N#Cc1cccc(S(=O)(=O)Nc2ccc(F)c3c(C#N)c[nH]c23)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 1/20 0.78
▸ ACLY P53396 6/20 0.55
▸ GLO1 Q04760 1/20 0.46
▸ SLC40A1 Q9NP59 1/20 0.46
▸ TRIM24 O15164 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ PTGES2 Q9H7Z7 2/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.44
▸ KIT P10721 1/20 0.43
▸ BRAF P15056 1/20 0.43
▸ FRK P42685 1/20 0.43
▸ SIK1 P57059 1/20 0.43
▸ MAP2K5 Q13163 1/20 0.43
▸ AURKB Q96GD4 1/20 0.43
▸ SRMS Q9H3Y6 1/20 0.43
▸ MAP3K20 Q9NYL2 1/20 0.43
▸ KAT6A Q92794 1/20 0.43
▸ PGR P06401 1/20 0.42
▸ PGAM1 P18669 1/20 0.42
▸ BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26844500 0.88 CRBN (0.74) CRBNACLYGLO1SLC40A1TRIM24
E-7820 SCHEMBL1581157 0.88 CRBN (1.00) CRBNACLYGLO1SLC40A1TRIM24
E-7820 SCHEMBL31237463 0.88 CRBN (1.00) CRBNACLYGLO1SLC40A1TRIM24
E-7820 SCHEMBL2950395 0.88 CRBN (1.00) CRBNACLYGLO1SLC40A1TRIM24
SCHEMBL21218179 0.87 CRBN (0.78) CRBNACLYGLO1SLC40A1TRIM24
SCHEMBL22428369 0.87 CRBN (0.82) CRBNACLYGLO1SLC40A1TRIM24
SCHEMBL21218180 0.87 CRBN (0.78) CRBNACLYGLO1SLC40A1TRIM24
SCHEMBL21218461 0.85 CRBN (0.76) CRBNACLYGLO1SLC40A1TRIM24
SCHEMBL21218177 0.84 CRBN (0.77) CRBNACLYGLO1SLC40A1TRIM24
SCHEMBL3060786 0.82 CRBN (0.71) CRBNACLYGLO1SLC40A1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807606-B2 Sulfonamide derivatives for protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-07 — — US disclosed
US-20200290964-A1 SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. 2020-09-17 — — US disclosed
WO-2019147783-A1 SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200290964-A1 SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION CUL5, CUL4A, DCAF1 CRBN 14/4885ACLY 2332/4885GLO1 2266/4885
US-11807606-B2 Sulfonamide derivatives for protein degradation CUL5, CUL4A, DCAF1 CRBN 14/4885ACLY 2332/4885GLO1 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback